Tang Capital takes 10% stake in Aurinia Pharma
Source: SeekingAlpha
2026-06-03 03:54:24 ET
More on Aurinia Pharma
- Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance
- Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade)
- Aurinia Pharma GAAP EPS of $0.25 beats by $0.05, revenue of $77.7M beats by $0.72M
- Aurinia Pharmaceuticals acquiring Kezar Life Sciences
- Seeking Alpha’s Quant Rating on Aurinia Pharma
Read the full article on Seeking Alpha
For further details see:
Tang Capital takes 10% stake in Aurinia Pharma
Aurinia Pharmaceuticals Inc
NASDAQ: AUPH
AUPH Trading
-1.34% G/L:
$16.18 Last:
500,241 Volume:
$16.46 Open:
AUPH Latest News
June 04, 2026 07:00:00 am
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
June 03, 2026 12:43:00 am
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
May 19, 2026 08:30:00 am
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
AUPH Stock Data
$1,932,123,392
126,527,384
2.24%
102
N/A
Biotechnology & Life Sciences
Healthcare
CA
Edmonton
